Paras Biopharma (Biologics CDMO) Finland is a Finnish biopharmaceuticals company having niche expertise in producing microbial-based biopharmaceutical products. After its inception in 2012, the company heavily focused on investing in developing microbial technologies for efficient production of microbial biologics. As a result of sustained efforts from the team comprising of protein scientists, bioprocess engineers and technologists and a strong experience in developing biologics in a most efficient manner, Paras Biopharma successfully developed these unique technologies having role in enabling and enhancing the production of intricate recombinant proteins. Paras Biopharma technologies have been successfully used for production of difficult-to-express proteins such as nanobodies, peptibodies, antibody fragments, long peptides, fusion proteins etc.
Company activities & offerings are categorized in 3 major areas:
1. Contract development & microbial biologics manufacturing (CDMO):
The company offers end-to-end services for production of microbial recombinant proteins. This includes the feasibility studies for expressing the intricate proteins by our technologies and scale up of the processes to large-scale. We offer fermentation services for small scale (10L), medium scale (150L) & large scale (750L or more).
2. Development of Recombinant expression systems and process technologies for biologics and biosimilars:
Paras Biopharma is actively engaged in research & development and is offering partnership for further development (including clinical development) on the following biosimilars: Recombinant IL1-RA / Anakinra (Kineret® Biosimilar), Analog Insulin Aspart and Recombinant Romiplostim (Nplate® Biosimilar). Further biologics are in the pipeline*.
Due to its own technologies, Paras Biopharma has achieved efficient and cost-effective ways which would help in the efficient production of some high value biosimilars. This development is based on Paras Biopharma's proprietary technology platform which includes Diabrid®, Noblecleav®, Biomultifold® and Cytofold StructQuant® technologies.
*Kineret® & Nplate® are registered trademarks of, SOBI Sweden and Amgen USA, respectively.
3. Recombinant Bioprocess Enzymes:
Paras Biopharma has developed and is offering Recombinant Bioprocess enzymes. These include Recombinant Enterokinase (RapidEK®) & Tev Protease (RapidTEV®) which are used in the cleavage of fusion proteins.
Paras Biopharma's Infrastructure and Facilities in Finland
Paras Biopharma fully owns a microbial production facility in Finland for the microbial production of recombinant products in microbial strains.
With a total floor area of 25,000 ft2 and a classified cleanroom of 4,300 ft2, other features include media and buffer preparation, live area (fermentation and harvest & extraction), purification suite (incl. +4°C cold room), final filtration and freeze-drying. Our team has strong experience in carrying out microbial biologics production.
We are ready to cater to biopharma needs for scale-up / commercial scale production.
Company activities & offerings are categorized in 3 major areas:
1. Contract development & microbial biologics manufacturing (CDMO):
The company offers end-to-end services for production of microbial recombinant proteins. This includes the feasibility studies for expressing the intricate proteins by our technologies and scale up of the processes to large-scale. We offer fermentation services for small scale (10L), medium scale (150L) & large scale (750L or more).
2. Development of Recombinant expression systems and process technologies for biologics and biosimilars:
Paras Biopharma is actively engaged in research & development and is offering partnership for further development (including clinical development) on the following biosimilars: Recombinant IL1-RA / Anakinra (Kineret® Biosimilar), Analog Insulin Aspart and Recombinant Romiplostim (Nplate® Biosimilar). Further biologics are in the pipeline*.
Due to its own technologies, Paras Biopharma has achieved efficient and cost-effective ways which would help in the efficient production of some high value biosimilars. This development is based on Paras Biopharma's proprietary technology platform which includes Diabrid®, Noblecleav®, Biomultifold® and Cytofold StructQuant® technologies.
*Kineret® & Nplate® are registered trademarks of, SOBI Sweden and Amgen USA, respectively.
3. Recombinant Bioprocess Enzymes:
Paras Biopharma has developed and is offering Recombinant Bioprocess enzymes. These include Recombinant Enterokinase (RapidEK®) & Tev Protease (RapidTEV®) which are used in the cleavage of fusion proteins.
Paras Biopharma's Infrastructure and Facilities in Finland
Paras Biopharma fully owns a microbial production facility in Finland for the microbial production of recombinant products in microbial strains.
With a total floor area of 25,000 ft2 and a classified cleanroom of 4,300 ft2, other features include media and buffer preparation, live area (fermentation and harvest & extraction), purification suite (incl. +4°C cold room), final filtration and freeze-drying. Our team has strong experience in carrying out microbial biologics production.
We are ready to cater to biopharma needs for scale-up / commercial scale production.
Focus Areas
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
